Kimer Med
Kimer Med is a New Zealand-based biotechnology company dedicated to ending the suffering caused by viral diseases through the development of safe and effective broad-spectrum antiviral therapeutics. Leveraging their proprietary platform for rapid antiviral drug design, Kimer Med targets the significant unmet need for treatments against the vast majority of human-infecting viruses, where 95% currently lack approved therapies. Among 21 viruses in total, they have demonstrated efficacy against all four serotypes of Dengue, as well as Zika virus, and a lead candidate is being advanced toward clinical trials. Kimer Med’s mission is to revolutionize antiviral treatment and enhance global health security by providing new, host-directed medical countermeasures to address currently untreatable viral diseases, and to stockpile for pandemic preparedness.
Industries
Nr. of Employees
small (1-50)
Kimer Med
56 Waimea Road Nelson South, Nelson 7010 New Zealand
Products
Lead broad‑spectrum antiviral protein candidate
A recombinant protein‑based antiviral candidate designed to bind long viral dsRNA in infected cells and trigger apoptosis, intended as a therapeutic against multiple virus families.
Lead broad‑spectrum antiviral protein candidate
A recombinant protein‑based antiviral candidate designed to bind long viral dsRNA in infected cells and trigger apoptosis, intended as a therapeutic against multiple virus families.
Expertise Areas
- Broad‑spectrum antiviral discovery
- Preclinical in vitro and in vivo evaluation
- Protein engineering and biologics formulation
- Virology assay development and mammalian cell culture
Key Technologies
- Recombinant protein therapeutics
- dsRNA‑targeting antiviral mechanism
- Apoptosis activation strategies
- Cell culture and CPE reduction assays
Key People
Rick Kiessig
Co-Founder & CEO, Chief Science Officer (CSO)
Dr Sophie Walker
Lead Scientist
Dr Lauren Nicol
Biomedical Scientist
Dr Geena McKenzie-Goldsmith
Biomedical Scientist
Dr Mauro Teixeira
Advisor
Rick Kiessig
Co-Founder & CEO, Chief Science Officer (CSO)
Dr Sophie Walker
Lead Scientist
Dr Lauren Nicol
Biomedical Scientist
Dr Geena McKenzie-Goldsmith
Biomedical Scientist
Dr Mauro Teixeira
Advisor
News & Updates
Named as an honoree in Fierce Biotech's 2024 'Fierce 15', recognizing the world's best and brightest in biotech.
Explores the complexities of Dengue fever, the challenges of developing treatments and vaccines for its four serotypes, and how Kimer Med’s approach targets a common viral process to overcome these barriers.
Highlights the importance of broad-spectrum antivirals for pandemic preparedness and Kimer Med’s alignment with global health priorities.
Announces a contract with Battelle Memorial Institute, funded by the US Defense Threat Reduction Agency, to develop antivirals for alphaviruses.
Highlights the global impact of flaviviruses and Kimer Med’s progress in developing antivirals for Dengue and Zika.
Emphasizes the importance of antiviral development for future pandemic response and Kimer Med’s commitment to this goal.
Named as an honoree in Fierce Biotech's 2024 'Fierce 15', recognizing the world's best and brightest in biotech.
Explores the complexities of Dengue fever, the challenges of developing treatments and vaccines for its four serotypes, and how Kimer Med’s approach targets a common viral process to overcome these barriers.
Highlights the importance of broad-spectrum antivirals for pandemic preparedness and Kimer Med’s alignment with global health priorities.
Announces a contract with Battelle Memorial Institute, funded by the US Defense Threat Reduction Agency, to develop antivirals for alphaviruses.
Highlights the global impact of flaviviruses and Kimer Med’s progress in developing antivirals for Dengue and Zika.
Emphasizes the importance of antiviral development for future pandemic response and Kimer Med’s commitment to this goal.